ADAPTIMMUNE LLC

GlaxoSmithKline and Novartis have completed their $16 billion asset swap deal, with GSK exchanging its oncology portfolio for Novartis's vaccines business, while also creating a joint consumer healthcare venture.

The FDA granted Breakthrough Therapy Designation to Adaptimmune's lete-cel for myxoid/round cell liposarcoma (MRCLS) treatment.

Adaptimmune's lete-cel demonstrated a 42% response rate in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma in a Phase II trial.

Adaptimmune's lete-cel met its primary endpoint in a Phase II trial for advanced or metastatic synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).

Adaptimmune's Lete-cel, a TCR-T cell therapy, demonstrated a 42% response rate in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

• Galapagos NV secured FDA IND clearance for GLPG5101, a CAR-T therapy, enabling U.S. patient recruitment for Phase II ATALANTA study in non-Hodgkin lymphoma. • The company is progressing over 15 programs, planning at least four IND-enabling studies in 2025, focusing on oncology and immunology. • Strategic collaborations with Blood Centers of America and Adaptimmune are expanding Galapagos' cell therapy manufacturing network and capabilities. • Galapagos maintains a strong cash position of EUR 3.3 billion, supporting its R&D efforts and business development opportunities in oncology and immunology.

Adaptimmune's Tecelra, a novel therapy for synovial sarcoma, has received FDA approval and is poised to deliver its first patient orders, marking a significant advancement in cancer treatment.

The FDA granted accelerated approval to afami-cel (Tecelra) for unresectable or metastatic synovial sarcoma in adults after prior chemotherapy.

The FDA granted Breakthrough Therapy designation to Adaptimmune's affinity-enhanced T-cell therapy targeting NY-ESO for synovial sarcoma, expediting its development.